Company intelligence / Profile preview

Regen Lab

Le Mont-sur-Lausanne, Vaud, Switzerlandregenlab.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Regen Lab’s medical devices for the preparation of autologous platelet-rich plasma and related cell therapies are CE-marked and cleared in multiple major markets. Their products have been used to treat over two million patients globally across musculoskeletal, dermatological, wound care, and intimate health indications. The company has published studies supporting safety and efficacy in these areas.

Therapeutic areas: Women's HealthDermatologyRheumatology
Modalities: DeviceCell therapy (autologous)Platelet-rich plasma therapy (PRP)Combination product (PRP + hyaluronic acid)
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

RegenPRP

Commercial

Indications: Tissue regeneration

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Regen Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regen Lab.

Explore the full profile